Vontobel Holding Ltd. Sells 16,097 Shares of IQVIA Holdings Inc. $IQV

Vontobel Holding Ltd. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,546 shares of the medical research company’s stock after selling 16,097 shares during the period. Vontobel Holding Ltd.’s holdings in IQVIA were worth $8,596,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sowell Financial Services LLC bought a new position in IQVIA during the first quarter worth about $305,000. Mather Group LLC. lifted its stake in IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after purchasing an additional 350 shares during the period. Patton Fund Management Inc. bought a new position in shares of IQVIA in the second quarter valued at approximately $231,000. Private Advisor Group LLC raised its stake in shares of IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after acquiring an additional 566 shares during the last quarter. Finally, Park Avenue Securities LLC raised its stake in shares of IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock valued at $956,000 after acquiring an additional 1,562 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV stock opened at $203.16 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50 day moving average price of $188.70 and a 200 day moving average price of $168.15. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The stock has a market capitalization of $34.54 billion, a PE ratio of 29.40, a price-to-earnings-growth ratio of 2.20 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the business earned $2.64 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IQV shares. Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research note on Thursday. Nineteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $236.45.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.